Drugs / BTZ-043
BTZ-043
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04874948 | Oct 2021 | lung disorder, pulmonary tuberculosis, respiratory tract infectious disorder | Michael Hoelscher | Completed | No outcome recorded |
| Phase 1 | NCT03590600 | Jun → Aug 2018 | lung disorder, pulmonary tuberculosis | Michael Hoelscher | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04044001 | Nov 2019 → Mar 2022 | pulmonary tuberculosis | Michael Hoelscher | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT06114628 | Jan 2024 → Feb 2027 expected | pulmonary tuberculosis | University College, London | Recruiting | No outcome recorded |
| Phase 2 | NCT05926466 | Sep 2023 → Aug 2024 | pulmonary tuberculosis | Michael Hoelscher | Unknown | No outcome recorded |
| Phase 2 | NCT05807399 | Apr 2023 → Oct 2027 expected | pulmonary tuberculosis | Michael Hoelscher | Recruiting | No outcome recorded |
| Phase 2 | NCT05382312 | Jul 2022 → May 2025 | tuberculosis | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BTZ-043 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05807399 ↗ |
| Known as | BTZ-10526043 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1822872 ↗ |
| Known as | Bzt043 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1822872 ↗ |
| Action | Inhibit | “BTZ-043, a first-in-class DprE1 inhibitor with strong bactericidal activity in murine models.” PMID 39793592 ↗ Jan 2025 |
| Modality | Small molecule | “BTZ-043 belongs to the chemical class of benzothiazinones” NCT05926466 ↗ |
| Route | Oral | “N=8, 125 mg BTZ-043 fasting, oral administration, powder and solvent for oral suspension, single dose” NCT03590600 ↗ |